Zevra Therapeutics (ZVRA) Equity Average (2016 - 2025)
Zevra Therapeutics (ZVRA) has disclosed Equity Average for 9 consecutive years, with $143.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 163.0% year-over-year to $143.9 million, compared with a TTM value of $143.9 million through Dec 2025, up 163.0%, and an annual FY2025 reading of $97.2 million, up 91.39% over the prior year.
- Equity Average was $143.9 million for Q4 2025 at Zevra Therapeutics, up from $125.2 million in the prior quarter.
- Across five years, Equity Average topped out at $143.9 million in Q4 2025 and bottomed at -$5.4 million in Q3 2022.
- Average Equity Average over 5 years is $68.6 million, with a median of $59.6 million recorded in 2023.
- The sharpest move saw Equity Average crashed 104.13% in 2022, then surged 1211.17% in 2023.
- Year by year, Equity Average stood at $116.7 million in 2021, then crashed by 67.73% to $37.7 million in 2022, then soared by 63.81% to $61.7 million in 2023, then fell by 11.31% to $54.7 million in 2024, then soared by 163.0% to $143.9 million in 2025.
- Business Quant data shows Equity Average for ZVRA at $143.9 million in Q4 2025, $125.2 million in Q3 2025, and $79.1 million in Q2 2025.